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a b s t r a c t
Background: Prostate cancer (PCa) diagnosis requires improvement with the aid of more accurate bio-
markers. Postejaculate urethral washings (PEUW) could be a physiological equivalent to urine obtained
following rectal prostaticmassage, the current basis for the prostate cancer antigen3 (PCA3) test. The aimof
this study was to investigate if PEUW contained prostate-based material, evidenced by the presence of
prostate specific antigen (PSA), and to evaluate the diagnostic performance of PEUW-based biomarkers.
Methods: Male patients referred for elevated serum PSA or abnormal digital rectal examination pro-
vided ejaculate and PEUW samples. PSA, PCA3, and b2-microglobulin (b2M) were quantified in ejaculate
and PEUW and compared with absolute and clinically significant (according to D’Amico criteria) PCa
presence, as determined by biopsies. Diagnostic performance was determined and compared with serum
PSA using receiver operating characteristic analysis.
Results: From 83 patients who provided PEUW samples, paired analysis with ejaculate samples was
possible for 38 patients, while analysis in an unpaired, extended cohort was possible for 62 patients. PSA
and PCA3 were detected in PEUW, normalized to b2M, and PCA3:PSA was calculated. In predicting ab-
solute PCa status, PCA3:b2M in ejaculate [area under the curve (AUC) 0.717] and PEUW (AUC 0.569) were
insignificantly better than PCA3:PSA (AUC 0.668 and 0.431, respectively) and comparable with serum PSA
(AUC 0.617) with similar trends observed for the extended cohort. When considering clinically significant
PCa presence, serum PSA in the comparison (AUC 0.640) and extended cohorts (AUC 0.665) was com-
parable with PCA3: b2M (AUC 0.667) and PCA3:PSA (AUC 0.605) in ejaculate, with lower estimates for
PEUW in the comparison (PCA3: b2M AUC 0.496; PCA3:PSA AUC 0.342) and extended (PCA3: b2M AUC
0.497; PCA3:PSA AUC 0.469) cohorts. The statistical analysis was limited by sample size.
Conclusion: PEUW contains prostatic material, but has limited diagnostic accuracy when considering
cell-derived DNA analysis. PCA3-based markers in ejaculate are comparable to serum PSA and digital
rectal examinationeurine markers.
Copyright © 2016 Asian Pacific Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The detection of prostate cancer (PCa) is fraught with difficulties
that include limitations of currently available biomarkers, access to
imaging and tissue sampling. Total serum prostatic specific antigen
(PSA) is currently the single most widely used marker clinically for
identifying men at risk of PCa, but it is a nonspecific indicator of
prostatic pathology that includes PCa among others so that popu-
lation and opportunistic screening is discouraged due to over-
investigation and over-detection, resulting in overtreatment.1
Contemporary PCa detection approaches have included, amongst
others, advocacy for a biomarker panel, the Prostate Health Index
and the 4-kallikrein protein test.2,3
Although imagingmodalities, such asmultiparametric magnetic
resonance imaging and even prostate specific membrane antigen
(PSMA) positron emission tomography, are being integrated into
the detection strategy for triaging patients with an elevated PSA
and may improve detection of clinically significant PCa,4 there are
limitations that detract from their widespread use. The false
negative rate (~15e20%) for multiparametric magnetic resonance
imaging suggests a significant proportion of clinically significant
tumors may be missed,4 which is also observed with PSMA-
positron emission tomography imaging of tumors that do not ex-
press PSMA.5 That imaging is establishing a niche in detection
strategies is undeniable; however, it is the cost of such imaging
methods that really limits application to mainstream clinical
practice. Improved patient selection for imaging with accurate
biomarkers is likely to optimize their practical application clinically.
Prostate-specific biofluids are an ongoing source for investiga-
tion using new analytical platforms.6 Prostate cancer antigen 3
(PCA3), a long noncoding RNA, collected in the first void of urine
following a vigorous digital rectal examination (DRE) or prostatic
massage, has been examined over the past 20 years,7 with studies
reporting to improve detection in men undergoing repeat biopsy,8
but its role clinically remains uncertain. Modifications of PCA3,9 as
well as a combination with TMPRSS2-ERG fusion gene have been
described to improve detection10 but have not been accepted as a
useful addition in routine patient testing.11 Other approaches uti-
lizing exosomes, proteomics, and metabolomics have the potential
to improve early diagnosis of localized disease.12e14 Indeed mo-
lecular and metabolomic markers in ejaculate or seminal fluid have
been reported to improve diagnosis compared to serum PSA.15e17
Paralleling the postmassage urine concept, collection of urine
following ejaculation, or postejaculate urethral washings (PEUW)
potentially represents a new source of prostate-specific biomarkers
for PCa detection and characterization, providing a physiologically
produced alternative to serum or digital prostatic massage effluent
for further biomarker discovery and development.
The aim of this study was to investigate the diagnostic potential
of selected molecular markers in PEUW in detecting PCa and
comparing diagnostic accuracy with the same markers in ejaculate,
as well as serum PSA. The hypothesis tested was that the diagnostic
performance of molecular markers in postejaculate urine would be
comparable with those in ejaculate or serum PSA.
2. Materials and methods
2.1. Patients
A clinical cohort of men (n ¼ 83) being investigated for PCa on
the basis of an abnormal DRE and/or elevated serum PSA provided
specimens of ejaculate and PEUW into sterile micro-urine jars,
containing 20 mL Hanks’ Balanced Salt Solution (Gibco, Life
Technologies Australia Pty Ltd, Scoresby, Victoria, Australia) and
empty urine jars, respectively, between January 2007 and
December 2009. As previously reported,15 all specimens were
processed within 2 hours of production after being delivered to the
hospital campus without cooling. All specimens were collected
prior to or at least 1 month following transrectal ultrasound guided
biopsy (TRUSbx) or transperineal template biopsy (TPBx).
Ethical approval to conduct this study was obtained from the
University of Queensland Medical Research Ethics Committee,
Brisbane, Australia (Project No. 2006000262) and the Royal Bris-
bane and Women’s Hospital, Human Research Ethics Committee,
Brisbane, Australia (HREC/09/QRBW/320, HREC/09/QRBW/305
together with 1995/088B).
2.2. Clinical data
All patient data were prospectively collected following recruit-
ment and included clinical details such as age, family history, and
serum PSA. Initial and updated TRUSbx/TPBx/radical prostatectomy
(RP) histology specimens were reviewed by D.P., J.P.-K., and H.S. and
reported according to the 2005 International Society of Urological
Pathology classification,18 including standard biopsy (number of
cores taken, number and percentage of positive cores, Gleason
score) and RP (gland size, Gleason score, pathological stage,
extracapsular status, and margin status) parameters.
In order to identify the patients for whom active treatment
would be recommended, risk stratification for biopsies in deter-
mining clinically significant PCa presence was performed using the
D'Amico criteria recommended in the American Urological Asso-
ciation Guidelines.19 The clinically significant PCa category
included patients defined as intermediate- and high-risk according
to the D'Amico criteria, while the absence of clinically significant
PCa was defined as low risk patients according to the D'Amico
criteria or those without PCa.19 The most accurate classification of
clinically significant PCa, based on histopathology from TRUSbx,
TPBx, and/or RP, was used given established disparity between
TRUSbx and RP histopathology. As previously reported, patients
were subsequently placed in one of two clinical groups based on
classification scheme used. Because of the imprecise nature of
TRUSbx in particular, patient follow-up was pursued for up to 7
years to ensure that those designated as negative for prostate
cancer really were negative.
2.3. Specimen processing and cellular isolation
Ejaculate specimens combined with 20 mL Hanks' Balanced Salt
Solution were layered over 10 mL isotonic Percoll (GE Health-
careePharmacia) and centrifuged at 974 g for 30e60 minutes at
4C, with supernatants subsequently collected in 1 mL aliquots,
snap-frozen on dry ice and stored at80C. The epithelial cell layer
at the Percoll interface, present as a discrete band suspended be-
tween supernatant above and sperm and noncellular components
below, was then pipetted, washed with 25 mL phosphate-buffered
saline or Hanks' and centrifuged at 1,258 g for 10 minutes at 4C.
2.4. RNA preparation
Total RNA from collected cells was isolated using TRIzol reagent
(Invitrogen) then subjected to on-column DNase treatment and
clean-up with the RNeasy kit (Qiagen). Low yield samples were
amplified using the SenseAmp kit (Gensisphere).
2.5. cDNA synthesis and quantitative reverse transcription
polymerase chain reaction
Quantitative reverse transcription polymerase chain reaction
(qPCR) was undertaken using the QIAGEN Quantitect SYBR green
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qPCR Mastermix (QIAGEN, Germany) on a Corbett Rotorgene ma-
chine 3000/6000 (Corbett Research, Australia). cDNA synthesis was
performed with 200e500 ng of total RNA reverse transcribed using
Superscript III (Invitrogen) and random hexamer primers (Prom-
ega). The synthesized cDNA was diluted 10-fold and 5 mL was used
for the assay in the presence of 7.5 mL Quantitect SYBR green
mastermix (Qiagen) and 5 pmol gene specific forward and reverse
primers. Each reaction was performed in triplicate for both patient
samples and calibrator. Reaction conditions were 95C for 15 mi-
nutes followed by 45 cycles of 20 seconds at 95C, 20 seconds at
58C, and 20 seconds at 72C. Data for each cycle were acquired at
the 72C step.
The genes that were characterized were b2-microglobulin (b2M),
PCA3, and PSA using the following primers (SigmaeAldrich,
Australia) for qPCR: b2M (forward: 50-AGCAGAGAATGGAAAGTCAAA-
30, reverse: 50-TGCTGCTTACATGTCTCG-30); PCA3 (forward: 50-
GGAAGGACCTGATGATACAGAGGTGAG-30, reverse: 50-CACAGGGC-
GAGGCTCATCG-30; PSA (forward: 50-GCATCAGGAACAAAAGCGTG-30,
reverse: 50-CCTGAGGAATCGATTCTTCA-30).
Standardized processing (including standard curve fitting, dy-
namic tube, slope correct) was performed for all runs using Rotor-
Gene 6000 Series Software version 1.7 (Corbett Research,
Australia). Tomaintain quality control, specimens with atypical melt
curves or quantitation curves below threshold for any single target
(with normal melt curves) were excluded. A standard threshold
value was manually set for each individual gene across all samples
and used to calculate cycle threshold (Ct) values, which were
exported to Excel (Microsoft Corporation, Redmond, WA, USA).
Based on average Ct (CtAv) and standard deviation (CtSD) values of
triplicates observed across all genes (see Fig. S1), cutoff points
defined for exclusion were CtAv > 35 and CtSD > 1.5 for PEUW and
ejaculate, as previously described.15 Analysis of PSA, PCA3, and b2M
in ejaculate and PEUW specimens was possible for 38 patients, with
these markers detected in PEUW only from 62 patients.
2.6. Relative gene expression determination
Relative gene expression was calculated using the method pre-
viously described by Pfaffl,20 which uses the following equation:
Expression ðRÞ ¼ EDCtðCalibratorsampleÞGOI
.
EDCtðCalibratorsampleÞRG
(1)
DCt (Calibrator-sample) estimates the amplification (Ct values)
difference between the calibrator reaction (uniform template
quantity to standardize all runs) and the target gene transcription
of the sample reaction (unknown).20 The reaction efficiency (E) of
the gene of interest (GOI) and endogenous reference gene (RG) are
considered without the required use of a standard curve in every
run, based on the assumption that reaction efficiency between
different runs was consistent and normalized by the calibrator
used.
2.7. Reference gene variation
b2M, a known housekeeping gene,7,21 was used as the endoge-
nous reference gene with subsequent relative gene expression
calculated for PSA and PCA3. The commercial use of PCA3, which,
unlike PSA, is highly overexpressed in prostate cancer,22 requires
PSA to be used as the reference gene on the basis of reports that PSA
expression is relatively constant and considers only cells of pros-
tatic origin so the expression of PCA3 relative to PSA was also
calculated.7
2.8. Data analysis
Relative gene expression results were analyzed considering
two clinical classifications, absolute PCa status (cancer vs. no
cancer) and clinically significant (present vs. absent) PCa status,
as determined using the D’Amico classification.19 Univariate
analysis was conducted with the nonparametric ManneWhitney
U test.
Receiver operating characteristic (ROC) analysis was per-
formed for each marker and compared to each other and serum
PSA, with binomial exact confidence interval and optimal cut
points for each marker calculated in Stata Statistical Software 13
(StataCorp. College Station, TX, USA) using the Liu23 method.
Significance thresholds were Bonferroni corrected (< 0.05/
4 ¼ < 0.0125) to adjust for multiple comparisons (n ¼ 4), and all
reported P values < 0.0125 were considered statistically
significant.
3. Results
3.1. Clinical characteristics
From 83 potential patients with adequate clinical data who
donated PEUW samples between January 2007 and December
2009, relative gene expression determination for PSA, PCA3, and
b2M was performed. Strict exclusion criteria (see Fig. S2) were
applied, resulting in sample exclusion due to unsatisfactory qPCR
analyses (atypical melt or quantitation curves, n ¼ 1), insufficient
cDNA to reach detection threshold (n ¼ 5), CtAv or CtSD outside
determined cutoffs (n ¼ 14) or coupled with an ejaculate sample
excluded for a similar reason (n¼ 25). Of the remaining 38 patients,
the relationships observed for the entire cohort with respect to
median (interquartile range) age [62 (57e68) years] and serum PSA
[6.7 (4.75e9.15) ng/mL] were preserved in this group, with a me-
dian age 62 (57e69) years (P> 0.0125 ) and serum PSA 6.3 (4.9e8.9)
ng/mL (P> 0.0125). Within the included 38 patients were 25 par-
ticipants having a prostate biopsy positive for cancer, with 21
deemed to have clinically significant PCa.
The demographic information of the cohort including median
(interquartile range) age, serum PSA, and relative expression ratios
of RNA markers for each group, absolute and clinically significant
PCa presence, are presented in Tables 1 and 2, respectively. Men
were of comparable ages in each classification group. Serum PSA
was similar for men diagnosed with PCa compared with men in the
no PCa group. This relationship was preserved for serum PSAwhen
comparing men with clinically significant PCa against those
without clinically significant PCa. Similar trends were observed in
the expanded cohort, which comprised 62 patients with 36 par-
ticipants with a positive prostate biopsy and 30 deemed to have
clinically significant PCa (Tables 1 and 2).
3.2. Biomarker performance
3.2.1. Absolute PCa status
When considering absolute PCa status (Table 1) and compared
to a chance area under the curve (AUC) of 0.500, serum PSA (AUC
0.617; P ¼ 0.217) and PSA:b2M (AUC ¼ 0.600; P ¼ 0.353) in PEUW
samples provided similar diagnostic performance. PCA3:b2M
(AUC¼ 0.569; P¼ 0.522) and. PCA3:PSA (AUC¼ 0.431; P¼ 0.528) in
PEUWdemonstrated inferior predictive ability. Similar results were
not observed in the expanded cohort, with serum PSA
(AUC ¼ 0.610, P ¼ 0.128) performing better than PSA:b2M
(AUC ¼ 0.506; P ¼ 0.935), PCA3:b2M (AUC ¼ 0.550; P ¼ 0.531), and
PCA3:PSA (AUC ¼ 0.529; P ¼ 728).
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In ejaculate, best diagnostic performance was observed for
PCA3:b2M (AUC ¼ 0.717; P ¼ 0.033), followed by PCA3:PSA
(AUC ¼ 0.668; P ¼ 0.078), followed by less impressive performance
for serum PSA (AUC 0.617; P ¼ 0.217), and poor performance of
PSA:b2M (AUC ¼ 0.486; P ¼ 0.895).
3.2.2. Clinically significant PCa
When considering clinically significant PCa (Table 2), similar
performance was observed for serum PSA (AUC¼ 0.640; P¼ 0.124),
PSA:b2M (AUC ¼ 0.608; P ¼ 0.269), and PCA3:PSA (AUC ¼ 0.342;
P¼ 0.093). The performance of PCA3:b2M (AUC¼ 0.496; P¼ 0.966)
was poorer and less predictive of clinically significant PCa. Within
the expanded cohort, only serum PSA (AUC ¼ 0.665; P ¼ 0.018)
performed as well, with poorer performance for the PEUW-based
PSA:b2M (AUC ¼ 0.525; P ¼ 0.740), PCA3:b2M (AUC ¼ 0.503;
P ¼ 0.967), and PCA3:PSA (AUC ¼ 0.469; P ¼ 0.681).
In ejaculate samples, PCA3:b2M (AUC ¼ 0.667, P ¼ 0.083) was
similar to serum PSA, and PCA3:PSA (AUC ¼ 0.605, P ¼ 0.263). The
performance of PSA:b2M (AUC ¼ 0.521, P ¼ 0.828) was less
impressive. For graphical purposes, comparison ROC curves are
available in Figs. S3 and S4 including the comparison P values
against the serum PSA AUC.
4. Discussion
PEUW could potentially be a new source of prostate-specific
biomarkers for PCa detection and characterization, providing an
alternative to serum and urine for further biomarker discovery and
development. Thus, we investigated in this study the utility of
prostatic cells in PEUW as a physiological source of PCa biomarkers.
We have shown that the diagnostic performance of themRNA-based
marker PCA3, normalized to PSA or b2M, in PEUW is likely to be
inferior to these markers in ejaculate, which were comparable to
serum PSA. Overall, the performance is similar to PCA3 in post-
massage urine in isolation (AUC 0.62),24 as well as in ejaculate in an
expanded cohort (AUC 0.625).15 PCA3 performed best in this cohort
in detecting absolute PCa status compared with clinically significant
PCa, in accordance with previous reports.10 This preliminary inves-
tigation helps to build on current PCa biomarker research literature.
The use of PEUW as a prostate-based biofluid is advantageous
for a number of reasons. First, it contains prostatic effluent
following ejaculation, indicated here by the presence of PSA. In
addition, there is no requirement for patient discomfort, in
contrast to prostatic massage. Furthermore, there is the potential
for tumor disruption and dissemination of malignant cells,25
Table 1
Demographic information for patients based on absolute cancer status (positive vs. negative biopsy).
Absolute cancer
status
Comparison cohort
No PCa (n ¼ 13); PCa (n ¼ 25)
Extended PEUW cohort
No PCa (n ¼ 26); PCa (n ¼ 36)
Demographic information ROC analysis Demographic information ROC analysis
No PCa, median
(IQR)
PCa, median (IQR) AUC (95% CI) Cutpoint Sn Sp No PCa, median
(IQR)
PCa, median(IQR) AUC (95% CI)
Age 65 (58.5e71) 63 (57e68.25) e e e e 64.5 (60e69) 63.5 (58e69) e
Serum PSA 6.20 (4.13e7.30) 6.50 (5.13e10.4) 0.617 (0.445e0.770) 9.05 36 100 6.30 (4.70e8.2) 7.00 (5.25e11.00) 0.610 (0.477e0.731)
PEUW PSA:b2M 0.07 (0.003e0.36) 0.10 (0.02e1.24) 0.600 (0.429e0.755) 0.006 84 46 0.32 (0.005e1.18) 0.15 (0.14e0.97) 0.506 (0.376e0.636)
PCA3:b2M 0.23 (0.01e0.60) 0.21 (0.06e1.24) 0.569 (0.399e0.728) 0.652 44 77 0.19 (0.02e0.48) 0.18 (0.07e0.99) 0.550 (0.419e0.677)
PCA3:PSA 2.72 (0.52e61.97) 1.45 (0.51e9.66) 0.431 (0.272e0.601) 0.764 72 38 1.24 (0.14e20.80) 1.19 (0.55e9.32) 0.529 (0.398e0.657)
Ejaculate PSA:b2M 0.07 (0.003e0.36) 0.03 (0.003e0.19) 0.514 (0.347e0.679) 0.003 80 38 e e e
PCA3:b2M 0.01 (0.004e0.10) 0.04 (0.02e0.28)* 0.717 (0.548e0.851) 0.023 72 77 e e e
PCA3:PSA 1.55 (0.12e2.80) 4.62 (0.77e11.84) 0.668 (0.496e0.812) 1.77 64 77 e e e
Median and interquartile range are shown for age and each marker in postejaculate urethral washing and ejaculate samples. All comparisons using the Mann-Whitney U test
(2-tailed; using a Bonferroni corrected threshold) were non-significant (P> 0.0125).
* P< 0.05 for area under curve with 95% confidence interval (AUC 95% CI) comparisons of markers with chance (AUC 0.5) as determined by the DeLong method. All com-
parisons between AUC estimates were nonsignificant (P> 0.0125).
b2M, b2-microglobulin; IQR, interquartile range; PCA3, prostate cancer antigen 3; PEUW, postejaculate urethral washings; PSA, prostate specific antigen; ROC, receiver
operating characteristic; Sn, sensitivity; Sp, specificity.
Table 2
Demographic information for patients based on clinically significant PCa classification.
Clinically significant
PCa
Comparison cohort
Absent (n ¼ 17); Present(n ¼ 21)
Extended PEUW cohort
Absent (n ¼ 32); Present (n ¼ 30)
Demographic information ROC analysis Demographic information ROC analysis
Absent, median
(IQR)
Present, median
(IQR)
AUC (95% CI) Cutpoint Sn Sp Absent, median
(IQR)
Present, median
(IQR)
AUC (95% CI)
Age 61 (56.25e69.5) 63 (57.75e69.25) e e e e 63.5 (58.5e68) 64 (58e70) e
Serum PSA 5.80 (4.38e7.30) 6.50 (5.28e13.43) 0.640 (0.468e0.789) 6.500 57 65 6.00 (4.55e8.20) 7.60 (5.50e11.90) 0.665 (0.534e0.780)*
PEUW PSA:b2M 0.04 (0.002e0.94) 0.10 (0.01e1.24) 0.608 (0.436e0.762) 0.006 86 41 0.21 (0.006e1.17) 0.18 (0.01e1.17) 0.525 (0.394e0.653)
PCA3:b2M 0.23 (0.02e1.13) 0.17 (0.04e1.08) 0.496 (0.330e0.662) 0.652 43 71 0.20 (0.02e0.72) 0.16 (0.04e0.93) 0.497 (0.367e0.627)
PCA3:PSA 2.77 (0.71e61.97) 1.11 (0.29e7.79) 0.342 (0.196e0.513) 0.764 67 29 1.58 (0.18e16.02) 1.03 (0.52e7.30) 0.469 (0.341e0.600)
Ejaculate PSA:b2M 0.03 (0.003e0.23) 0.03 (0.003e0.31) 0.521 (0.353e0.685) 0.014 67 47 e e e
PCA3:b2M 0.02 (0.004e0.25) 0.04 (0.02e0.28) 0.667 (0.495e0.811) 0.023 71 65 e e e
PCA3:PSA 1.56 (0.44e6.58) 3.42 (0.66e16.1) 0.605 (0.434e0.759) 1.77 62 65 e e e
Median and interquartile range are shown for age and each marker in postejaculate urethral washing and ejaculate samples. All comparisons using the Mann-Whitney U test
(2-tailed; using a Bonferroni corrected threshold) were non-significant (P> 0.0125).
* P< 0.05 for area under curve with 95% confidence interval (AUC 95% CI) comparisons of markers with chance (AUC 0.5) as determined by the DeLong method. All com-
parisons between AUC estimates were nonsignificant (P> 0.0125).
b2M, b2-microglobulin; IQR, interquartile range; PCA3, prostate cancer antigen 3; PEUW, postejaculate urethral washings; PSA, prostate specific antigen; ROC, receiver
operating characteristic; Sn, sensitivity; Sp, specificity.
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given known elevations in serum PSA after TRUSBx and DRE.26
Reports regarding serum PSA elevation after ejaculation are
mixed, with levels reported to return to normal after 48 hours,27
thus PEUW following global contraction of the prostate gland
with ejaculation can be considered a physiological equivalent of
nonphysiological postmassage urine. PEUW sampling enables
postcoital donation, which may be more acceptable for some men
and has been used to investigate infertility. The combination of
urine and ejaculatory components in PEUW allows for assessment
of markers reflecting local (ejaculate) and systemic (urine) pa-
thology. While this enables use in clinical scenarios where sys-
temic biological alterations are important to monitor, such as
active surveillance and metastatic disease, it is also a potential
drawback of PEUW, because the local pathology markers in the
ejaculate component can be confounded by the systemic contri-
butions from the urine component. These may contribute to the
lower diagnostic performance of PEUW compared to ejaculate
described here.
The benefits that we have previously outlined for the use of
ejaculate as a prostate-based biofluid also apply to PEUW. Specif-
ically, ejaculate contains malignant prostatic epithelial cells,28 with
cell-derived molecular markers PCA3 and hepsin shown to be
comparable diagnostically with PCA3 in post-massage urine.15
Analysis of microRNAs in cell-derived mRNA in ejaculate has been
reported to improve PCa detection, with miR-200b combined with
serum PSA (AUC ¼ 0.751) significantly better than serum PSA alone
(AUC ¼ 0.555).16 We have previously reported the use of a com-
posite score, created using contributions from serum PSA, and
ejaculatory micro RNAs-125b, and -200c, to significantly improve
PCa detection (AUC ¼ 0.869) compared with serum PSA alone
(AUC¼ 0.672; P< 0.05).15 The ability to provide an ejaculate sample
may also indicate a favorable performance status and consequent
survival benefit, with a high and significantly better overall and
PCa-specific survival benefit observed for these patients at 10 years,
15 years, and 20 years.29 Incorporation of exosome and metab-
olome analysis may improve predictive accuracy using these non-
invasively obtained biofluids,12,30 reducing anxiety and uncertainty
for clinicians and patients managed by active surveillance, in
addition to assisting with PCa testing. Use of PEUW may be more
favorable than ejaculate as PEUW samples can be provided in the
comfort of the home environment and postintercourse, a strategy
more likely to be used by men than the sterile surrounds of the
clinic setting. Similar to urine cytology, the sample could be stored
overnight in a refrigerator and brought to the clinic the morning
after, assuming RNA integrity is maintained.
The aim of this comparative study was to investigate the diag-
nostic potential of selected molecular markers in PEUWs in
detecting PCa on the basis of the D’Amico classification bench-
mark,19 widely used to stratify in the past. However, the goal posts
are in the process of being changed as it is being realized increas-
ingly that intermediate risk PCa is not one condition but a spectrum
of conditions. Recently, the management strategy of active sur-
veillance has been extended to include some Gleason 3þ 4 (ISUP 2)
tumors regarded as favorable by the National Comprehensive
Cancer Network (NCCN) formenwith a life-expectancy< 10 years31
with this change supported by the American Society of Clinical
Oncology.32 By inference, this means that not all intermediate-risk
tumors can be considered as clinically significant. However, for the
purpose of comparison, risk classifications such as that proposed by
D'Amico remain relevant until the entity of clinically significant can
be defined better.
The limitations of this preliminary, exploratory study include the
small sample size resulting in large confidence intervals and low
statistical power. Biologically, the potential for low ejaculatory
contribution or dilution reducing the prostate-specific RNA yield
may impair results. PCA3:PSA levels in PEUW were lower in men
with PCa, both in the comparison and expanded cohorts, resulting in
ROC estimates below 0.5, which was the inverse of that observed for
ejaculate samples and other published reports. Although the sample
drop-out rates were similar for PEUW and ejaculate, with positive
PSA signals suggesting the presence of prostatic material in both
sample sets, these results suggest malignant cells may dominate in
the ejaculate. A potential explanation for this are changes in cell
adhesion molecules, which have been recognized for some time in
PCa,33withmost attention focused on E-cadherin. Loss of E-cadherin
is particularly evident in more aggressive tumors with cadherin
switching also recently described.34 Thus, disaggregated cells or cell
clusters from aggressive tumorsfirst appear in ejaculate as a result of
global contraction of prostatic smooth muscle following accumula-
tion in acini prior to ejaculation. This in turn may cause relatively
fewer cancerous cells to be present in the urethra from the latter part
of the ejaculate, whichwould be dislodgedwith subsequent voiding.
As a result, PEUW may contain fewer cancerous cells but does
contain prostate epithelial cells, evidenced here by the presence of
PSA. Thus, in patients suspected to harbor nonaggressive PCa, the
presence of prostatic cells in PEUWwith lowexpression of PCA3may
help determinewhich patients have nonaggressive PCa amenable to
active surveillance or watchful waiting.
In conclusion, we introduced and investigated PEUW as a
physiological source of PCa biomarkers. We found that PEUW
contains prostatic cells, as evidenced by PSA signal. However,
significantly upregulated PCA3 levels, consistent with those re-
ported for malignant tissue, were only observed in ejaculate
specimens. PEUW may yet prove to be a useful source of cell-free
secreted markers, as opposed to cell-derived markers. Further
biomarker development using these prostate-specific biofluidsmay
result in improved diagnosis and monitoring of PCa, reducing
anxiety and doubt for the benefit of clinicians and patients.
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